Effect Of Rilapladib (SB-659032) On Platelet Aggregation

A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00387257

Enrollment

Registered

2006-10-12

Start date

2006-10-31

Completion date

2007-04-30

Last updated

2015-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Healthy Subjects

Keywords

platelet aggregation, SB-659032, rilapladib

Brief summary

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Interventions

DRUGRilapladib (SB-659032)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects with QTc \< 450 msec as measured at screening.

Exclusion criteria

* History of asthma. * Smokers.

Design outcomes

Primary

Measure	Time frame
Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry.	on Day 35 (or 21 days post last dose) as determine by optical aggregometry

Secondary

Measure	Time frame
Collagen EC50 values on Day 1 and Day 14 as determined by optical aggregometry Plasma Lp-PLA2 activity Clinical safety data Concentrations of rilapladib and SB-664601.	on Day 1 and Day 14 as determined by optical aggregometry

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026